Status:
NOT_YET_RECRUITING
Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection
Lead Sponsor:
Spanish Society of Cardiology
Collaborating Sponsors:
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Conditions:
Spontaneous Coronary Artery Dissection
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Spontaneous coronary artery dissection (SCAD) is a cause of acute coronary syndrome (ACS). Most patients are treated with beta-blockers (BB) and antiplatelet drugs (AP) on empiric basis. The Beta-Bloc...
Detailed Description
Spontaneous coronary artery dissection (SCAD) is a relatively rare but important and increasingly recognized cause of acute coronary syndrome (ACS). Most patients presenting with SCAD are treated with...
Eligibility Criteria
Inclusion
- Angiographic diagnosis of SCAD
- Admission for ACS or other manifestations of ischemia
- Informed consent
Exclusion
- Cardiogenic shock or severe hemoynamic instability
- Concomitant severe heart disease requiring surgical correction (in \<2 years)
- Medical condition seriously limiting life expectancy (\< 2 years)
- Allergies or contraindication to drugs required in one of the study arms; the patient may be randomized in the other arm (factorial design)
Key Trial Info
Start Date :
April 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04850417
Start Date
April 30 2021
End Date
December 31 2028
Last Update
April 20 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.